{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:34:44Z","timestamp":1793662484102,"version":"4.5.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI153355"],"award-info":[{"award-number":["R01AI153355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI153355"],"award-info":[{"award-number":["R01AI153355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI153355"],"award-info":[{"award-number":["R01AI153355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI153355"],"award-info":[{"award-number":["R01AI153355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI153355"],"award-info":[{"award-number":["R01AI153355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Artemisinin combination therapies (ACTs) are highly effective at treating uncomplicated\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria, but the emergence of the new\n                    <jats:italic>pfkelch13<\/jats:italic>\n                    R561H mutation in Rwanda, associated with delayed parasite clearance, suggests that interventions are needed to slow its spread. Using a Rwanda-specific spatial calibration of an individual-based malaria model, we evaluate 26 strategies aimed at minimizing treatment failures and delaying the spread of R561H after 3, 5 and 10\u2009years. Lengthening ACT courses and deploying multiple first-line therapies (MFTs) reduced treatment failures after 5\u2009years when compared to the current approach of a 3-d course of artemether\u2013lumefantrine. The best among these options (an MFT policy) resulted in median treatment failure counts that were 49% lower and a median R561H allele frequency that was 0.15 lower than under baseline. New approaches to resistance management, such as triple ACTs or sequential courses of two different ACTs, were projected to have a larger impact than longer ACT courses or MFT; these were associated with median treatment failure counts in 5\u2009years that were 81\u201392% lower than the current approach. A policy response to currently circulating artemisinin-resistant genotypes in Africa is urgently needed to prevent a population-wide rise in treatment failures.\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02551-w","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:02:40Z","timestamp":1695297760000},"page":"2775-2784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-483X","authenticated-orcid":false,"given":"Robert J.","family":"Zupko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran Dang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Claude S.","family":"Ngabonziza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michee","family":"Kabera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-5900","authenticated-orcid":false,"given":"Thu Nguyen-Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien Trung","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Uwimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0830-9630","authenticated-orcid":false,"given":"Maciej F.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2551_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50\u201355 (2014).","journal-title":"Nature"},{"key":"2551_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411\u2013423 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2551_CR3","unstructured":"Report on Antimalarial Drug Efficacy, Resistance and Response: 10 Years of Surveillance (2010\u20132019) (World Health Organization, 2020); https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336692\/9789240012813-eng.pdf"},{"key":"2551_CR4","unstructured":"World Malaria Report 2021 (World Health Organization, 2021); https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2021"},{"key":"2551_CR5","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602\u20131608 (2020).","journal-title":"Nat. Med."},{"key":"2551_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana, A. et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect. Dis. 21, 1120\u20131128 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"2551_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann, C. et al. Increase in Kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda.Emerg. Infect. Dis. 27, 294 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"2551_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3201\/eid2804.212269","volume":"28","author":"W van Loon","year":"2022","unstructured":"van Loon, W. et al. In vitro confirmation of artemisinin resistance in Plasmodium falciparum from patient isolates, Southern Rwanda, 2019. Emerg. Infect. Dis. 28, 852\u2013855 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"2551_CR9","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer, J., Gandhi, P., Renner, K. C. & Schmitt, E. K. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J. Infect. Dis. 225, 1411\u20131414 (2022).","journal-title":"J. Infect. Dis."},{"key":"2551_CR10","doi-asserted-by":"publisher","first-page":"ofad149","DOI":"10.1093\/ofid\/ofad149","volume":"10","author":"R Kirby","year":"2023","unstructured":"Kirby, R. et al. Examining the early distribution of the artemisinin-resistant Plasmodium falciparum kelch13 R561H mutation in areas of higher transmission in Rwanda. Open Forum Infect. Dis. 10, ofad149 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"2551_CR11","doi-asserted-by":"publisher","first-page":"e01818-18","DOI":"10.1128\/AAC.01818-18","volume":"63","author":"V Asua","year":"2019","unstructured":"Asua, V. et al. Changing molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob. Agents Chemother. 63, e01818-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2551_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua, V. et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J. Infect. Dis. 223, 985\u2013994 (2021).","journal-title":"J. Infect. Dis."},{"key":"2551_CR13","unstructured":"Strategy to Respond to Antimalarial Drug Resistance in Africa (World Health Organization, 2022); https:\/\/www.who.int\/publications\/i\/item\/9789240060265"},{"key":"2551_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-452","volume":"13","author":"Y Lubell","year":"2014","unstructured":"Lubell, Y. et al. Artemisinin resistance\u2014modelling the potential human and economic costs. Malar. J. 13, 452 (2014).","journal-title":"Malar. J."},{"key":"2551_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-236","volume":"11","author":"C Karema","year":"2012","unstructured":"Karema, C. et al. Trends in malaria cases, hospital admissions and deaths following scale-up of anti-malarial interventions, 2000\u20132010, Rwanda. Malar. J. 11, 236 (2012).","journal-title":"Malar. J."},{"key":"2551_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3","volume":"17","author":"C Amaratunga","year":"2019","unstructured":"Amaratunga, C. et al. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments\u2014a WWARN individual patient data meta-analysis. BMC Med. 17, 1 (2019).","journal-title":"BMC Med."},{"key":"2551_CR17","unstructured":"WHO Guidelines for Malaria\u201414 March 2023 (WHO Global Malaria Programme, 2023); https:\/\/app.magicapp.org\/#\/guideline\/7089"},{"key":"2551_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1963-0","volume":"16","author":"S Whegang Youdom","year":"2017","unstructured":"Whegang Youdom, S., Tahar, R. & Basco, L. K. Comparison of anti-malarial drug efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis. Malar. J. 16, 311 (2017).","journal-title":"Malar. J."},{"key":"2551_CR19","unstructured":"Seasonal Malaria Chemoprevention with Sulfadoxine\u2013Pyrimethamine Plus Amodiaquine in Children: A Field Guide (World Health Organization, 2013); https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/85726\/9789241504737_eng.pdf"},{"key":"2551_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0035-9203(00)90082-8","volume":"94","author":"M van Vugt","year":"2000","unstructured":"van Vugt, M. et al. Artemether\u2013lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94, 545\u2013548 (2000).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"2551_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2404-4","volume":"17","author":"KM Tun","year":"2018","unstructured":"Tun, K. M. et al. Effectiveness and safety of 3 and 5 day courses of artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malar. J. 17, 258 (2018).","journal-title":"Malar. J."},{"key":"2551_CR22","doi-asserted-by":"publisher","first-page":"e01140-19","DOI":"10.1128\/AAC.01140-19","volume":"64","author":"MA Onyamboko","year":"2020","unstructured":"Onyamboko, M. A. et al. A randomized controlled trial of three- versus five-day artemether-lumefantrine regimens for treatment of uncomplicated Plasmodium falciparum malaria in pregnancy in Africa. Antimicrob. Agents Chemother. 64, e01140-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2551_CR23","unstructured":"U.S. President\u2019s Malaria Initiative Rwanda: Malaria Operational Plan FY 2022 (U.S. President\u2019s Malaria Initiative, 2021); https:\/\/d1u4sg1s9ptc4z.cloudfront.net\/uploads\/2022\/01\/FY-2022-Rwanda-MOP.pdf"},{"key":"2551_CR24","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/S2666-5247(22)00155-0","volume":"3","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study. Lancet Microbe 3, e701\u2013e710 (2022).","journal-title":"Lancet Microbe"},{"key":"2551_CR25","doi-asserted-by":"publisher","first-page":"e0002200","DOI":"10.1371\/journal.pgph.0002200","volume":"3","author":"TD Nguyen","year":"2023","unstructured":"Nguyen, T. D., Tran, T. N.-A., Parker, D. M., White, N. J. & Boni, M. F. Antimalarial mass drug administration in large populations and the evolution of drug resistance. PLoS Glob. Public Health 3, e0002200 (2023).","journal-title":"PLoS Glob. Public Health"},{"key":"2551_CR26","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni, M. F., Smith, D. L. & Laxminarayan, R. Benefits of using multiple first-line therapies against malaria. Proc. Natl Acad. Sci. USA 105, 14216\u201314221 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2551_CR27","doi-asserted-by":"publisher","first-page":"e1001984","DOI":"10.1371\/journal.pmed.1001984","volume":"13","author":"MF Boni","year":"2016","unstructured":"Boni, M. F., White, N. J. & Baird, J. K. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med. 13, e1001984 (2016).","journal-title":"PLoS Med."},{"key":"2551_CR28","doi-asserted-by":"publisher","unstructured":"Boni, M. F. Breaking the cycle of malaria treatment failure. Front. Epidemiol. https:\/\/doi.org\/10.3389\/fepid.2022.1041896 (2022).","DOI":"10.3389\/fepid.2022.1041896"},{"key":"2551_CR29","doi-asserted-by":"publisher","first-page":"e000371","DOI":"10.1136\/bmjgh-2017-000371","volume":"2","author":"HD Schallig","year":"2017","unstructured":"Schallig, H. D. et al. Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Glob. Health 2, e000371 (2017).","journal-title":"BMJ Glob. Health"},{"key":"2551_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm, R. W. et al.Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet 395, 1345\u20131360 (2020).","journal-title":"Lancet"},{"key":"2551_CR31","doi-asserted-by":"publisher","first-page":"e1008850","DOI":"10.1371\/journal.pcbi.1008850","volume":"17","author":"A Kunkel","year":"2021","unstructured":"Kunkel, A., White, M. & Piola, P. Novel anti-malarial drug strategies to prevent artemisinin partner drug resistance: a model-based analysis. PLoS Comput. Biol. 17, e1008850 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"2551_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39914-3","volume":"14","author":"TD Nguyen","year":"2023","unstructured":"Nguyen, T. D. et al. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat. Commun. 14, 4568 (2023).","journal-title":"Nat. Commun."},{"key":"2551_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-83","volume":"11","author":"JL Cohen","year":"2012","unstructured":"Cohen, J. L., Yavuz, E., Morris, A., Arkedis, J. & Sabot, O. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda. Malar. J. 11, 83 (2012).","journal-title":"Malar. J."},{"key":"2551_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2370-x","volume":"17","author":"K Banek","year":"2018","unstructured":"Banek, K., Webb, E. L., Smith, S. J., Chandramohan, D. & Staedke, S. G. Adherence to treatment with artemether\u2013lumefantrine or amodiaquine\u2013artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malar. J. 17, 222 (2018).","journal-title":"Malar. J."},{"key":"2551_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","volume":"7","author":"NJ White","year":"2007","unstructured":"White, N. J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7, 549\u2013558 (2007).","journal-title":"Lancet Infect. Dis."},{"key":"2551_CR36","doi-asserted-by":"publisher","first-page":"e1003766","DOI":"10.1371\/journal.pmed.1003766","volume":"18","author":"XHS Chan","year":"2021","unstructured":"Chan, X. H. S. et al. The cardiovascular effects of amodiaquine and structurally related antimalarials: an individual patient data meta-analysis. PLoS Med. 18, e1003766 (2021).","journal-title":"PLoS Med."},{"key":"2551_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1188-2","volume":"16","author":"IL Haeusler","year":"2018","unstructured":"Haeusler, I. L., Chan, X. H. S., Gu\u00e9rin, P. J. & White, N. J. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med. 16, 200 (2018).","journal-title":"BMC Med."},{"key":"2551_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cid\/ciac783","volume":"76","author":"ME Whalen","year":"2023","unstructured":"Whalen, M. E. et al. The impact of extended treatment with artemether\u2013lumefantrine on antimalarial exposure and reinfection risks in Ugandan children with uncomplicated malaria: a randomized controlled trial. Clin. Infect. Dis. 76, 443\u2013452 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"2551_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski, B. et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect. Dis. 17, 174\u2013183 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"2551_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","volume":"18","author":"R Amato","year":"2018","unstructured":"Amato, R. et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect. Dis. 18, 337\u2013345 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"2551_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1752-4571.2008.00067.x","volume":"2","author":"W Pongtavornpinyo","year":"2009","unstructured":"Pongtavornpinyo, W. et al. Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evol. Appl. 2, 52\u201361 (2009).","journal-title":"Evol. Appl."},{"key":"2551_CR42","doi-asserted-by":"publisher","first-page":"e66277","DOI":"10.7554\/eLife.66277","volume":"10","author":"BH Stokes","year":"2021","unstructured":"Stokes, B. H. et al. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. eLife 10, e66277 (2021).","journal-title":"eLife"},{"key":"2551_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04071-3","volume":"21","author":"D Hakizimana","year":"2022","unstructured":"Hakizimana, D. et al. The impact of COVID-19 on malaria services in three high endemic districts in Rwanda: a mixed-method study. Malar. J. 21, 48 (2022).","journal-title":"Malar. J."},{"key":"2551_CR44","unstructured":"World Malaria Report 2022 (World Health Organization, 2022); https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022"},{"key":"2551_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-04026-0","volume":"21","author":"A Gansan\u00e9","year":"2022","unstructured":"Gansan\u00e9, A. et al. Design and methods for a quasi-experimental pilot study to evaluate the impact of dual active ingredient insecticide-treated nets on malaria burden in five regions in sub-Saharan Africa. Malar. J. 21, 19 (2022).","journal-title":"Malar. J."},{"key":"2551_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03649-7","volume":"20","author":"P Tindana","year":"2021","unstructured":"Tindana, P. et al. Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations. Malar. J. 20, 119 (2021).","journal-title":"Malar. J."},{"key":"2551_CR47","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2551_CR48","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","volume":"3","author":"TD Nguyen","year":"2015","unstructured":"Nguyen, T. D. et al. Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob. Health 3, e758\u2013e766 (2015).","journal-title":"Lancet Glob. Health"},{"key":"2551_CR49","doi-asserted-by":"publisher","first-page":"e0000111","DOI":"10.1371\/journal.pgph.0000111","volume":"2","author":"RJ Zupko","year":"2022","unstructured":"Zupko, R. J. et al. Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLoS Glob. Public Health 2, e0000111 (2022).","journal-title":"PLoS Glob. Public Health"},{"key":"2551_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0140-6736(19)31097-9","volume":"394","author":"DJ Weiss","year":"2019","unstructured":"Weiss, D. J. et al. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000\u201317: a spatial and temporal modelling study. Lancet 394, 322\u2013331 (2019).","journal-title":"Lancet"},{"key":"2551_CR51","unstructured":"Demographic and Health Survey 2019\/2020\u2014Key Indicators (National Institute of Statistics of Rwanda, 2020); https:\/\/www.statistics.gov.rw\/publication\/demographic-and-health-survey-20192020-key-indicators"},{"key":"2551_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/srep05678","volume":"4","author":"A Wesolowski","year":"2014","unstructured":"Wesolowski, A. et al. Quantifying travel behavior for infectious disease research: a comparison of data from surveys and mobile phones. Sci. Rep. 4, 5678 (2014).","journal-title":"Sci. Rep."},{"key":"2551_CR53","doi-asserted-by":"publisher","first-page":"e1004267","DOI":"10.1371\/journal.pcbi.1004267","volume":"11","author":"A Wesolowski","year":"2015","unstructured":"Wesolowski, A., O\u2019Meara, W. P., Eagle, N., Tatem, A. J. & Buckee, C. O. Evaluating spatial interaction models for regional mobility in Sub-Saharan Africa. PLoS Comput. Biol. 11, e1004267 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"2551_CR54","unstructured":"Rwanda Malaria Operational Plan FY 2019 (U.S. President\u2019s Malaria Initiative, 2019); https:\/\/www.pmi.gov\/where-we-work\/rwanda\/"},{"key":"2551_CR55","unstructured":"Rwanda Malaria Operational Plan FY 2020 (U.S. President\u2019s Malaria Initiative, 2020); https:\/\/www.pmi.gov\/where-we-work\/rwanda\/"},{"key":"2551_CR56","unstructured":"Rwanda Districts (World Bank Group, 2018); https:\/\/datacatalog.worldbank.org\/search\/dataset\/0041453"},{"key":"2551_CR57","unstructured":"World Boundaries GeoDatabase (World Bank Group, 2020); https:\/\/datacatalog.worldbank.org\/search\/dataset\/0038272\/World-Bank-Official-Boundaries"},{"key":"2551_CR58","unstructured":"Rwanda\u2014Water Bodies (Lakes) (OCHA, 2018); https:\/\/data.humdata.org\/dataset\/rwanda-water-bodies?"},{"key":"2551_CR59","unstructured":"Protected Planet: The World Database on Other Effective Area-Based Conservation Measures (WD-OECM) (UNEP-WCMC and IUCN, 2023); https:\/\/resources.unep-wcmc.org\/products\/4c1733823f2a451e8d5ecbaaef3f1a06"},{"key":"2551_CR60","unstructured":"Rwanda Vital Statistics Report\u20142020 (National Institute of Statistics of Rwanda, 2021); http:\/\/www.statistics.gov.rw\/publication\/1705"},{"key":"2551_CR61","unstructured":"Rwanda Malaria Indicator Survey (RMIS), Final Report 2017 (Malaria and Other Parasitic Diseases Division of the Rwanda Biomedical Center Ministry of Health, 2018); https:\/\/dhsprogram.com\/publications\/publication-MIS30-MIS-Final-Reports.cfm"},{"key":"2551_CR62","unstructured":"Rwanda Health Sector Performance Report 2017\u20132019 (Republic of Rwanda, Ministry of Health, 2020); https:\/\/www.moh.gov.rw\/fileadmin\/user_upload\/Moh\/Publications\/Reports\/FINAL_Annual_Report_2017-2019_02062020.pdf"},{"key":"2551_CR63","unstructured":"World Population Prospects 2019: Volume II: Demographic Profiles (United Nations, 2019); https:\/\/population.un.org\/wpp\/Publications\/Files\/WPP2019_Volume-II-Demographic-Profiles.pdf"},{"key":"2551_CR64","doi-asserted-by":"publisher","unstructured":"Hersbach, H. et al. Complete ERA5 from 1940: fifth generation of ECMWF atmospheric reanalyses of the global climate. Copernicus https:\/\/doi.org\/10.24381\/cds.143582cf (2023).","DOI":"10.24381\/cds.143582cf"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02551-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T05:10:29Z","timestamp":1700716229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2551"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02551-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.12.22283369","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}